Singapore markets closed
Straits Times Index
3,316.56 -6.06 (-0.18%) Nikkei
38,646.11 -457.11 (-1.17%) Hang Seng
18,608.94 -259.77 (-1.38%) FTSE 100
8,317.59 -21.64 (-0.26%) Bitcoin USD
68,950.60 -221.17 (-0.32%) CMC Crypto 200
1,481.26 +13.16 (+0.90%)
NVO Dec 2024 135.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:59PM EDT. Market open.
| Previous close | 14.68 |
| Open | 13.92 |
| Bid | 14.20 |
| Ask | 14.80 |
| Strike | 135.00 |
| Expiry date | 2024-12-20 |
| Day's range | 13.92 - 14.82 |
| Contract range | N/A |
| Volume | |
| Open interest | 134 |
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy
Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy are included in this Analyst Blog.
ZacksWhy This 1 Medical Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
BenzingaNovo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet on May 24 to review Novo Nordisk A/S’s (NYSE:NVO) application seeking approval for a once-weekly insulin icodec. In December 2023, the FDA said that data submitted by Novo Nordisk during the regulatory review is considered to constitute a major amendment to the Biologics License Application (BLA) for insulin icodec. Therefore, the regulatory review is extended by three months to provide time for a full submissio
© 2024 Yahoo. All rights reserved.